Search
for
Sort by
Research 841–870 of 1000+
- FC 2-2 : Therapeutic Effects of Growth Factor Cocktail (CellcurinTM) containing FGF5s (fibroblast growth factor 5 short) and NMN (nicotinamide mononucleotide) applied on the scalp in the patients with androgenetic alopecia: a split study
- A randomised trial of 5% minoxidil versus combination of 5% minoxidil and oral spironolactone in treatment of female pattern hair loss
- Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss
- Dual effects of 5α-reductase inhibitor dutasteride on androgenetic alopecia and acne vulgaris
- Systemic cyproterone acetate and 5% minoxidil topical in the treatment of female pattern hair loss
- Faculty Opinions recommendation of Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
- Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata
- Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
- Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up
- The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride
- Constitutive Internalization of the Leucine-rich G Protein-coupled Receptor-5 (LGR5) to the Trans-Golgi Network
- Chronic telogen effluvium: A study of 5 patients over 7 years
- Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial
- Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
- Isolation rearing-induced reduction of brain 5α-reductase expression: Relevance to dopaminergic impairments
- The extract of Thujae occidentalis semen inhibited 5α-reductase and androchronogenetic alopecia of B6CBAF1/j hybrid mouse
- Biochemical Roles of Testosterone and Epitestosterone to 5α-Reductase as Indicators of Male-Pattern Baldness
- Diffuse hypertrichosis during treatment with 5% topical minoxidil
- Doping-Control Analysis of the 5α-Reductase Inhibitor Finasteride: Determination of Its Influence on Urinary Steroid Profiles and Detection of Its Major Urinary Metabolite
- MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen<sup>1</sup>
- Decreased fertility in male rats administered the 5α-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation
- Intracrine and Myotrophic Roles of 5α-Reductase and Androgens
- Minoxidil increases 17β-hydroxysteroid dehydrogenase and 5α-reductase activity of cultured human dermal papilla cells from balding scalp
- Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
- Age-related changes in brain and pituitary 5α-reductase with finasteride (Proscar) treatment
- Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment
- Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor.